NIH Awards Grant for Research on APX3330 as Treatment for Cancer Cachexia

INDIANAPOLIS, Ind. – Researchers will continue to explore the impact of Apexian’s target molecule, APX3330, on cancer cachexia with additional grant funding from the National Institutes of Health (NIH) National Cancer Institute (NCI). Cancer cachexia is weight loss with chronic inflammation and defective metabolism, which causes roughly one-third of all cancer deaths. It is particularly prevalent in pancreatic ductal adenocarcinoma (PDAC), which has a dismal … Read more…

Kelley Presents at National Institutes of Health

Dr. Mark Kelley, Chief Scientific Officer of Apexian Pharmaceuticals, presented a special seminar at the National Institutes of Health on October 3 on his research on APX3330’s effect on the Ref-1/APE signaling node in cancer and chemotherapy-induced neuropathy. In addressing the National Institute of Environmental Health Sciences, Dr. Kelley discussed the progress of this promising therapy from benchtop to the current phase 1 clinical trial.